论文部分内容阅读
目的探讨艾迪注射液联合化疗治疗中晚期肺癌的临床疗效。方法将68例中晚期肺癌患者随机分为治疗组35例和对照组33例。对照组在第1,8天给予重酒石酸长春瑞滨注射液25mg/m2,第1～3天给予顺铂30mg/m2;治疗组化疗方案同对照组,同时给予艾迪注射液50mL加入5%葡萄糖注射液450mL中静脉滴注,qd;连用10d为1周期,每间隔21d重复治疗,共3～4个周期。两组病例均给予格拉司琼止吐治疗。结果治疗组近期有效率为68.57%,对照组近期有效率为39.39%(P<0.05);生活质量改善率(等级提高)治疗组为77.14%,对照组为48.48%(P<0.05);治疗组不良反应发生率分别为血红细胞42.86%,白细胞40.00%,血小板45.71%,厌食28.57%,恶心、呕吐28.57%;对照组不良反应发生率分别为血红细胞66.67%,白细胞69.70%,血小板69.70%,厌食42.42%,恶心、呕吐54.55%。结论艾迪注射液可作为一种有效的化疗增效减毒剂,配合化疗治疗中晚期肺癌。
Objective To investigate the clinical efficacy of Aidi Injection combined with chemotherapy in the treatment of advanced lung cancer. Methods 68 patients with advanced lung cancer were randomly divided into treatment group 35 cases and control group 33 cases. In the control group, vinorelbine tartrate injection 25mg / m2 was given on day 1,8 and cisplatin 30mg / m2 on days 1 to 3. The chemotherapy in the treatment group was the same as that in the control group. At the same time, 50 mL of Aidi Injection was added to 5% Glucose injection 450mL intravenous infusion, qd; continuous use of 10d for a period of 21d repeat treatment, a total of 3 to 4 cycles. Two groups of patients were given granisetron antiemetic treatment. Results The effective rate was 68.57% in the treatment group, 39.39% in the control group (P <0.05), 77.14% in the quality of life improvement group and 48.48% in the control group (P <0.05) The rates of adverse reactions were 42.86% for erythrocytes, 40.00% for white blood cells, 45.71% for platelets, 28.57% for anorexia, 28.57% for nausea and vomiting. The incidence of adverse reactions in control group were 66.67% for red blood cells, 69.70% for white blood cells, 69.70% , Anorexia 42.42%, nausea, vomiting 54.55%. Conclusion Aidi injection can be used as an effective chemotherapy synergistic attenuator, with chemotherapy for advanced lung cancer.